Find AiViva at 2026 BIO International Convention

Looking forward to attending BIO International Convention 2026 in San Diego and meeting colleagues across the biotech, pharmaceutical, investment, academic, nonprofit, and government communities.

At AiViva BioPharma, we are advancing two clinical-stage programs:

• AIV007, a periocular, sustained-release lenvatinib therapy being developed for retinal vascular diseases, including wet AMD and DME.
• AIV001, an intradermally administered axitinib therapy being investigated for scar management and non-melanoma skin cancer.

Both programs are supported by human clinical data and leverage our proprietary JEL™ localized drug-delivery technology designed to provide sustained exposure while minimizing systemic drug levels.

We welcome discussions regarding strategic partnerships, regional licensing, co-development opportunities, and potential investment relationships.

If you will be attending BIO 2026, I would be pleased to connect.